EUVIMEDEUVIMED entdecken
ValidierungsstudieKlinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials

Andrew J Armstrong iD, Vinnie Y T Liu iD, Ramprasaath R Selvaraju, Emmalyn Chen, Jeffry P Simko, Sandy DeVries, Oliver Sartor iD, Howard M Sandler iD, Osama Mohamad iD, Huei-Chung Huang, Jacqueline Griffin, Rikiya Yamashita und 15 weitere

Journal of Clinical Oncology · 10.11.2025 · 43 (32) · 3494-3504

DOI: 10.1200/jco.24.00365 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.11.2025. Verfasst von Andrew J Armstrong und 26 weiteren Autor:innen. Beteiligte Einrichtung: Duke University Medical Center, Durham, NC. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Artificial Intelligence, Androgen Antagonists, Biomarkers, Tumor. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Long-term androgen deprivation therapy (ADT) improves survival in men with high-risk localized prostate cancer (PCa) receiving radiotherapy (RT). Predictive biomarkers are needed to guide ADT duration. METHODS A multimodal artificial intelligence (MMAI)–derived predictive biomarker was trained for long-term (LT) versus short-term (ST) ADT using pretreatment digital prostate biopsy images and clinical data (age, prostate-specific antigen, Gleason, and T stage) from six NRG Oncology phase III randomized radiotherapy trials. The novel MMAI-derived biomarker was developed to predict the differential benefit of LT-ADT on the primary end point, distant metastasis (DM). MMAI predictive utility was validated on a seventh randomized trial, RTOG 9202 (N = 1,192), which randomly assigned men to RT + ST-ADT (4 months) versus RT + LT-ADT (28 months). Fine-Gray and cumulative incidence analyses for DM, and secondarily, death with DM, were performed. Deaths without DM were treated as competing risks. RESULTS In the validation cohort (median follow-up, 17.2 years), LT-ADT significantly improved DM from 26% to 17% (subdistribution hazard ratio [sHR], 0.64 [95% CI, 0.50 to 0.82], P < .001). A significant biomarker-treatment predictive interaction was observed ( P = .04) for DM, whereby MMAI biomarker–positive men (n = 785, 66%) had reduced DM with LT-ADT versus ST-ADT (sHR, 0.55 [95% CI, 0.41 to 0.73], P < .001), whereas no treatment benefit was observed for MMAI biomarker–negative men (n = 407; sHR, 1.06 [95% CI, 0.61 to 1.84], P = .84). The estimated 15-year DM risk difference between RT + LT-ADT and RT + ST-ADT was 14% in MMAI biomarker–positive men and 0% in MMAI biomarker–negative men. The MMAI biomarker was also prognostic for DM, irrespective of treatment (sHR, 2.35 [95% CI, 1.72 to 3.19], P < .001). CONCLUSION To our knowledge, the MMAI model is the first validated predictive biomarker to guide ADT duration with RT in localized/locally advanced PCa. Approximately one third of men with high-risk PCa could safely be spared the additional 24 months of ADT and the associated morbidity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsArtificial IntelligenceAndrogen AntagonistsBiomarkers, TumorHumansMaleAgedMiddle AgedClinical Trials, Phase III as TopicRandomized Controlled Trials as Topic

Substanzen

Androgen AntagonistsBiomarkers, Tumor

Autor:innen und Institutionen

  • Duke University Medical Center, Durham, NC.
  • Artera Inc, Los Altos, CA.
  • University of California San Francisco, San Francisco, CA.
  • Mayo Clinic, Rochester, MN.
  • Cedars-Sinai Medical Center, Los Angeles, CA.
  • University of Maryland, Baltimore, MD.

ORCID-Profile: Andrew J Armstrong, Vinnie Y T Liu, Oliver Sartor, Howard M Sandler, Osama Mohamad, Phuoc T Tran, Daniel E Spratt, Steve P Lee, Ali El-Gayed, Rana McKay, Todd Morgan, Felix Y Feng

Förderung

  • NCI NIH HHS

Zitieren

APA

Armstrong, A. J., Liu, V. Y. T., Selvaraju, R. R., Chen, E., Simko, J. P., DeVries, S., Sartor, O., Sandler, H. M., Mohamad, O., Huang, H. C., Griffin, J., Yamashita, R., Esteva, A., Tran, P. T., Spratt, D. E., Carson, J. H., Peters, C., Gore, E., Lee, S. P., …, & Nguyen, P. L. (2025). Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials. Journal of Clinical Oncology, 43(32), 3494-3504. https://doi.org/10.1200/jco.24.00365

Vancouver

Armstrong AJ, Liu VYT, Selvaraju RR, Chen E, Simko JP, DeVries S, et al. Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials. Journal of Clinical Oncology. 2025;43(32):3494-3504. doi:10.1200/jco.24.00365

BibTeX
@article{Armstrong2025,
  author = {Armstrong, Andrew J and Liu, Vinnie Y T and Selvaraju, Ramprasaath R and Chen, Emmalyn and Simko, Jeffry P and DeVries, Sandy and Sartor, Oliver and Sandler, Howard M and Mohamad, Osama and Huang, Huei-Chung and Griffin, Jacqueline and Yamashita, Rikiya and Esteva, Andre and Tran, Phuoc T and Spratt, Daniel E and Carson, John Hi and Peters, Christopher and Gore, Elizabeth and Lee, Steve P and Monson, Jedidiah M and Augspurger, Mark E and El-Gayed, Ali and Rodgers, Joseph P and McKay, Rana and Morgan, Todd and Feng, Felix Y and Nguyen, Paul L},
  title = {Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {32},
  pages = {3494--3504},
  doi = {10.1200/jco.24.00365}
}
Kostenlos starten →